Monte Rosa Therapeutics Inc (GLUE)vsRegeneron Pharmaceuticals Inc (REGN)
GLUE
Monte Rosa Therapeutics Inc
$8.64
-3.03%
HEALTHCARE · Cap: $880.99M
REGN
Regeneron Pharmaceuticals Inc
$920.69
-0.19%
HEALTHCARE · Cap: $98.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 23926% more annual revenue ($16.90B vs $70.33M). REGN leads profitability with a 28.5% profit margin vs -186.2%. REGN earns a higher WallStSmart Score of 80/100 (B+).
GLUE
Hold36
out of 100
Grade: F
REGN
Strong Buy80
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GLUE.
Margin of Safety
+36.9%
Fair Value
$1497.56
Current Price
$920.69
$576.87 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 325.8% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 30.4%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -26.4% — below average capital efficiency
Negative free cash flow — burning cash
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GLUE
The strongest argument for GLUE centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 325.8% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 30.4%. Revenue growth of 36.3% demonstrates continued momentum.
Bear Case : GLUE
The primary concerns for GLUE are EPS Growth, Market Cap, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score.
Key Dynamics to Monitor
GLUE profiles as a hypergrowth stock while REGN is a growth play — different risk/reward profiles.
GLUE carries more volatility with a beta of 1.38 — expect wider price swings.
GLUE is growing revenue faster at 325.8% — sustainability is the question.
REGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
REGN scores higher overall (80/100 vs 36/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Monte Rosa Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively break down therapeutically relevant proteins. The company is headquartered in Boston, Massachusetts.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?